

LETTERS AND  
CORRESPONDENCE

Letters and correspondence submitted for possible publication must be identified as such. Text length must not exceed 500 words and five bibliographic references. A single concise figure or table may be included if it is essential to support the communication. Letters not typed double-spaced will not be considered for publication. Letters not meeting these specifications will not be returned to authors. Letters to the Editor are utilized to communicate a single novel observation or finding. Correspondence is to be used to supplement or constructively comment on the contents of a publication in the journal and cannot exceed the restrictions for Letters to the Editor. The Editor reserves the right to shorten text, delete objectional comments, and make other changes to comply with the style of the journal. Permission for publication must be appended as a postscript. Submissions must be sent to Paul Chervenick, M.D., Editor of Brief Reports/Letters to Editors, American Journal of Hematology, H. Lee Moffitt Cancer Center, University of South Florida, 12902 Magnolia Drive, Tampa, FL 33612 to permit rapid consideration for publication.

### All-trans Retinoic Acid-Induced Multiple Mononeuropathies

*To the Editor:* All-trans retinoic acid (ATRA) is widely used as a differentiation therapy to induce a complete remission in patients with acute promyelocytic leukemia (APL) [1]. The major adverse effect during ATRA therapy is an increase of leukocytes, which is often accompanied by retinoic acid syndrome [2]. This reaction is characterized by fever, respiratory distress, radiographic pulmonary infiltrates, pleural effusions, and weight gain [3]. It has also been reported that ATRA-associated neurological symptoms such as headache and pseudotumor cerebri [4] are mainly caused by intracranial hypertension. We describe a patient who developed multiple mononeuropathies during ATRA therapy for APL.

A 23-year-old Japanese female was admitted with fever and purpura in November 1997. APL with disseminated intravascular coagulation was diagnosed. She received ATRA (45 mg/m<sup>2</sup>/day) with chemotherapy including daunorubicin (40 mg/m<sup>2</sup>/day, on days 9, 10, 21, and 22) and behenoyl cytarabine (200 mg/m<sup>2</sup>/day, on days 9, 10, 11, 21, 22, and 23), and supportive therapy for disseminated intravascular coagulation. She had a slight headache after administration of ATRA, but there were no findings on the neurological examination and computed tomography scan of the brain. On the seventeenth day after admission, a neurosurgical operation was performed because of acute subdural hematoma. Although ATRA-associated headache persists, no symptoms remained, which were caused by intracranial hemorrhage and operation. Furthermore, she complained of diplopia, and burning pain and contact dysaesthesiae at the dorsum of the left hand and the right foot on day 21 of the ATRA treatment. She also had weakness in the same extremities. Tendon reflexes were normal. Electrophysiologic study revealed a decrease of right peroneal nerve conduction velocity and amplitude. Although right abducens nerve palsy and visual disturbance were present, there were no papilloedema and abnormalities on magnetic resonance imaging of the brain. Lumbar puncture showed normal cerebrospinal fluid with normal pressure. She had no manifestation of autonomic disturbances. ATRA was discontinued because a complete remission was achieved on day 51 after administration of ATRA. Total dosage of ATRA was 3,390 mg. She received three times the intensive

postremission chemotherapy (daunorubicin, cytarabine, mitoxantrone, mercaptopurine, and prednisolone). Symptoms of peripheral neuropathy and findings on electrophysiologic study gradually improved as well as headache and dry skin after discontinuation of ATRA, in spite of additional chemotherapy. The right abducens nerve palsy also partially improved.

To the best of our knowledge, this is the first report of ATRA-induced multiple mononeuropathies. Neurological symptoms might be considered as atypical pseudotumor cerebri with focal neurological sign [5]. However, there was no evidence of intracranial hypertension. Furthermore, we carefully excluded a possibility that other medication including anticancer drugs induced peripheral neuropathy. Clinicians should be aware of this potential side effect in patients receiving ATRA.

SATOSHI YAMAJI  
HEIWA KANAMORI  
AKI MISHIMA  
SHIN FUJISAWA  
SHIGEKI MOTOMURA  
HIROSHI MOHRI

*The First Department of Internal Medicine, Yokohama City University School of Medicine, Yokohama, Japan*

### REFERENCES

- Huang ME, Ye YC, Chen SR, Chai JR, Lu JX, Zhou L, Gu LJ, Wang ZY: Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. *Blood* 72:567–572, 1988.
- Frankel SR, Eardley A, Lauwers G, Weiss M, Warrell RP Jr: The "retinoic acid syndrome" in acute promyelocytic leukemia. *Ann Intern Med* 117:292–296, 1992.
- Warrell RP, Jr., de The H, Wang ZY, Degos L: Acute promyelocytic leukemia. *N Engl J Med* 329:177–189, 1993.
- Digre KB, Corbet JJ: Pseudotumor cerebri in men. *Arch Neurol* 45:866–872, 1988.
- Round R, Keane JR: The minor symptoms of increased intracranial pressure: 101 patients with benign intracranial hypertension. *Neurology* 38:1461–1464, 1988.

### Soft Drink Abuse, Malnutrition, and Folic Acid Deficiency

*To the Editor:* Herein, we report a 28-year-old woman who presented with severe macrocytic anemia in November 1996. Her past medical history was unremarkable except for asthma and one episode of acute synovitis a few years earlier. Her blood count was normal two years earlier.

She is a housekeeper who drank alcohol very rarely and used nonsteroidal anti-inflammatory drugs occasionally. She presented with a history of weakness, a 7.5 kg weight loss in the past two months and of nausea, vomiting, and loss of appetite in the last three weeks. Her food intake for this period consisted almost exclusively of the soft drink Coca-Cola. There was no malabsorption symptoms. Physical examination revealed a severe obesity (126 kg, 1.58 m, body mass index over 50). She was slightly icteric and her tongue was reddened and smooth with papillary atrophy. The neurological examination was normal. The first blood count showed a severe anemia with a hemoglobin (Hg) of 51 g/l, a hematocrit of 0.147 L/L (0.37–0.47), a mean corpuscular volume (MCV) of 99.5 fl (normal 82–94), and reticulocytes at 1.8%. Leukocytes were reduced to  $3.3 \times 10^9$  g/l (normal 150–450).

Blood smear revealed a marked anisocytosis, no ovalocytosis, quite a few dacryocytes, polychromatophilia, and erythroblasts. A discrete myeloma with a left shift was noted; there were no hypersegmented neutro-

phils. The biochemical analysis was remarkable only for an elevated lactate dehydrogenase level (3,198 U/l) and bilirubin (52  $\mu\text{mol/l}$ ). Serum levels of proteins and albumin were normal as was the iron status. However, serum level of folic acid showed a severe deficiency with values below 1.3 nmol/l (normal above 3.5, deficiency below 2.5). Serum level of vitamin B12 was 100 pmol/l (normal above 150, deficiency below 100). Intrinsic factor antibody was negative.

A malabsorption evaluation was performed, including duodenal biopsies, and was noncontributory. A bone marrow aspiration was performed and was compatible with megaloblastic anemia; there was a marked erythroid dysplasia, a few giant metamyelocytes, and the myeloid on erythroid ratio fell to 1.5:1. Alkaline phosphatase of leukocytes score was elevated (212, normal 20–80). Haptoglobin was undetectable and direct Coombs' test was negative. Hepatic function tests, including viral serologies were normal, as were the thyroid function tests. The sucrose hemolysis test and Ham's acid hemolysis test were negative.

A careful review of the patient's dietary habits showed poor nutrition, consisting mostly of bread, rice, potatoes, liver, and a great amount of dairy products. She regularly ate snacks consisting of candies, ice cream, and potato chips. However, what was most remarkable was the consumption of approximately three liters of Coca-Cola per day. This soft drink does not contain any folic acid and has no known folic acid inhibitor. Dietary evaluation showed an energetic intake of 1,500 kcal per day, 40 mg of proteins per day, and 70 mg per day of folic acid (normal is 185 mg per day). The patient received one transfusion of packed red cells, 1,000 mg of B12 vitamins and folic acid, 5 mg IV for one dose, then 5 mg po die for four days, 10 mg po die for two days, 15 mg po die for two months followed by 5 mg po die for two months. Then it was stopped. She also received nutritional counseling.

The patient improved rapidly with disappearance of her symptoms of weakness and vomiting. Ten days after beginning her treatment, her blood count showed a Hb increase from 51 to 79 g/l, and an MCV of 97 fl; reticulocytes were increased at 18%. Platelets were still at  $141 \times 10^9$  g/l but leukocytes were normal. Seventeen days later, Hb was 105 g/l and platelets were normal.

After one year of follow-up, her blood count remains normal; serum levels of folic acid and vitamin B12 are normal. She is taking neither folic acid nor B12 vitamin supplements. Her diet has improved but remains deficient.

This case is one of severe macrocytic anemia due to a severe deficit in folic acid. This is the first case to our knowledge in which excessive consumption of soft drinks combined with malnutrition is reported as the main cause of folic acid deficiency. This deficiency has been reported so far mainly in a population of alcoholics and substance abusers. The underlying mechanism has not been elucidated.

It is interesting to note that this patient was severely obese, suggesting that malnutrition must not be overlooked, even in this population; intake of vitamins and elements is expected to be sufficient but quality of intake may cause a significant deficiency in one or more of these.

Finally, it is a reminder that nutrition status must be well assessed and that counseling is crucial.

**GUYLAINE GAUDET**


*Fellow in Hematology, Hôpital du Sacré-Cœur de Montréal, Affiliated Hospital, University of Montreal, Canada*

**JACQUES LAPLANTE**

*Hemato-Oncologist, Hôpital du Sacré-Cœur de Montréal, Affiliated Hospital, University of Montreal, Canada*

### Sex Difference in Myeloperoxidase Activity of Neutrophils

*To the Editor:* Activated neutrophils produce several antimicrobial oxygen metabolites, including superoxide anion, hydrogen peroxide, hydroxyl



**Fig. 1.** The mean MPXI of neutrophils in normal men and women.

radicals, hypochlorous acid, and single oxygen [1]. These reactive metabolites are generated by a reduced nicotinamide adenine dinucleotide phosphate (NADPH)-dependent oxidase, located on the plasma membrane, and a myeloperoxidase (MPO), located in the lysosome [2]. The former three metabolites are produced even in MPO deficiency, so it may be difficult to consider that MPO deficiency is one of the causes for clinically significant failure of neutrophil function. However, in some patients with MPO deficiency, the cytotoxic activities against bacteria and fungi are decreased in neutrophils [3,4]. Therefore, measurement of MPO activity in neutrophils may be useful for evaluating a part of the defense mechanism. Recently, an automated hematology system, which differentiates white blood cells, has come into widespread use. With this system, MPO activity, which represents the MPO staining intensity, is measured as the mean myeloperoxidase index (MPXI) of neutrophils. In this study, therefore, we examined MPO activities of neutrophils in normal subjects.

The subjects studied were 41 normal men (mean age, 36 years; range, 19–57 years), and 46 normal women (mean age, 32 years; range, 21–47 years). The MPXI of peripheral blood was measured using the automated hematology analyzer THMS-H2 (Bayer Technicon, Tarrytown, NY). We found that the MPXI in normal women ( $n = 46$ ,  $0.3 \pm 2.7$ , mean  $\pm$  SD,  $P < 0.01$ ) was significantly higher than that in normal men ( $n = 41$ ,  $-1.8 \pm 2.4$ ) (Fig. 1). This sex difference suggests that some microbicidal activity may be stronger in women than in men. In support of this finding, it was reported in mass surveys that the infection rate of women was lower than that in men in the tinea of dermatophytic infection [5]. Furthermore, this suggests that sex steroid hormones may affect MPO activity, that is the MPXI. Indeed, we found that the change of the MPXI in a woman synchronized with that of basal body temperature and that of serum concentration of estradiol with some phase shift, during three menstrual cycles. However, the MPXI in a man did not change during the 12 weeks of measurement. Also, the results of nitro blue tetrazolium (NBT) reduction and neutrophil number did not change during this period in both subjects. To study the direct effect of sex hormone on the MPO activity, we exam-

ined the changes of MPXI 2 and 3 hr after the addition of estrone (5,000 pg/mL), B-estradiol (5,000 pg/mL), estriol (5,000 pg/mL), or testosterone (100 ng/mL) to peripheral blood in vitro, but we found no effect.

Taken together, these data indicate that: 1. the MPXI of neutrophils, which is measured easily by an automated hematological analyzer and represents MPO activity, is higher in women than in men; 2. the menstrual cycle affects the MPXI; and 3. the MPXI may be useful as a partial index for microbicidal activity of neutrophils.

OSAMU KABUTOMORI  
TAKEHIKO YANAGIHARA

The Central Laboratory for Clinical Investigation, Osaka University  
Hospital, Osaka, Japan

YOSHINORI IWATANI

Department of Clinical Laboratory Science, Faculty of Medicine, Osaka  
University, Osaka, Japan

ATSUSHI KAWARAZAKI  
MIWAKO KABUTOMORI

Kawarazaki Hospital, Osaka, Japan

#### REFERENCES


- Borregaard N. Bactericidal mechanisms of the human neutrophil. *Scand J Haematol* 1984;32:225-230.
- Cumutte JT, Babior BM. Composition of neutrophils. In: Williams WJ, Beutler E, Erslev AJ, Lichman MA, editors. *Hematology*. 4th ed. New York: McGraw-Hill Book Co.; 1990. p 770-774.
- Cech P, Papathanassiou A, Boreux G, Roth P, Miescher PA. Hereditary myeloperoxidase deficiency. *Blood* 1979;53:403-411.
- Lehrer RI, Cline MJ. Leukocyte myeloperoxidase deficiency and disseminate candidiasis. *J Clin Invest* 1969;48:1478-1488.
- Nowicki R. Dermatophytoses in the Gdansk area. Poland. A 12-year survey. *Mycoses* 1996;39:399-402.

### Case of Hepatosplenic $\gamma\delta$ T-Cell Lymphoma Presenting With Severe Hypersplenism

*To the Editor:* Pancytopenia with severe neutropenia at presentation is a rare finding in hepatosplenic  $\gamma\delta$  T-cell lymphoma (TCL) [1-4].

In March 1997, an 18-year-old male was hospitalized with fever, abdominal discomfort, and fatigue. Despite the absence of either superficial or profound lymphadenopathies as confirmed by a computerized tomographic scan of the chest, abdomen and pelvis, hepatomegaly with massive splenomegaly, 3 and 23 cm below the costal margins, respectively, were noted. The peripheral blood count showed pancytopenia and severe neutropenia (Hb 6.3 g/dl, Hct 20%, platelets  $20 \times 10^9/l$ , leukocytes  $2 \times 10^9/l$ , neutrophils  $0.68 \times 10^9/l$ ). No abnormal cells were detected in the peripheral blood and in the bone marrow (aspirate and biopsy). Biochemistry results were within normal limits except moderate elevations in alkaline phosphatase, lactic dehydrogenase, and  $\beta_2$ -microglobulin levels. In May 1997, splenectomy was performed. Histologic examination of the spleen showed atrophy of the germinal centers, with partial destructions of the white pulp. The red pulp seemed expanded with its sinusoids homogeneously infiltrated with lymphoid cells, which were positive for LCA and CD3. A similar infiltration pattern was observed in the hepatic sinusoids.

After splenectomy, the liver enlarged to the umbilicus. The pancytopenia improved (Hb 11.7 g/dl, Hct 34.7%, platelets  $256 \times 10^9/l$ , neutrophils  $4 \times 10^9/l$ ) but the peripheral blood smear showed atypical lymphoid cells varying between 35% and 45%. A second bone marrow biopsy three months after splenectomy showed an infiltration with the same neoplastic cells in a diffuse interstitial pattern. In the immunophenotyping of peripheral blood after splenectomy with flow cytometry, the ratio of the  $\gamma\delta$  T-cell receptor



**Fig. 1.** Polyacrylamide gel electrophoresis with TCR V $\gamma$ 1 and V $\gamma$ 2 primers after PCR amplification. (PCR with TCR V $\gamma$ 1 and V $\gamma$ 2 primers were for lanes 1 to 4 and 6 to 9, respectively. Lanes 1 and 6: case A; lanes 2 and 7: our patient; lanes 3 and 8: positive control; lanes 4 and 9: typical polyclonal smear sample from normal lymphocytes; lane 5: Marker-BM no. VIII)

(TCR) bearing lymphoid cells was 59%. CD2, CD3, CD5, CD7, and CD56 positivity ranged between 70 and 99%. The heteroduplex analysis of peripheral blood showed that this pattern carried the monoclonal TCR V $\gamma$ -1 gene (Fig. 1).

The patient did not respond to chemotherapy. Neither regimens with conventional doses (CHOP: cyclophosphamide, doxorubicin, vincristine, and prednisone) nor that with high doses of methotrexate and/or cytosine arabinoside (NHL-BFM-90) proved to be effective. In May 1998 his condition deteriorated progressively and he died 13 months after diagnosis.

The presence of pancytopenia with severe neutropenia at presentation, seems to be an uncommon manifestation as it has been observed in only three of the 23 patients with hepatosplenic  $\gamma\delta$  TCL reported in the medical literature until the time of this writing [3,4]. Thus, the patient presented seems to be the fourth case displaying this feature. Another important finding in this case was the presence of hypersplenism due to the infiltration of the red pulp of the spleen in a manner resembling that seen in hairy cell leukemia. Splenectomy has, similarly, corrected this hypersplenism only by increasing the number of peripheral blood cells [5] without any effect on the disease process, progression being evident by the appearance of abnormal lymphoid cells in the peripheral blood. Thus, despite high-dose chemotherapy, the course of the disease was concluded as progressive in this case due to the persistence of B symptoms, increased hepatomegaly, and peripheral blood involvement. It can also be concluded that hypersplenism may also account for the cytopenias besides bone marrow infiltration and that splenectomy, like chemotherapy, seems ineffective in altering the progressive course of the disease.

#### ACKNOWLEDGMENTS

The Authors are indebted to Prof. Dr. Andrea Biondi (Milan, Italy) for his help and interest and who kindly performed the heteroduplex analysis of the peripheral blood.

GÜNÇAĞ DİNÇOL  
MELİHA NALÇACI  
A. SELİM YAVUZ  
HÜSEYİN KEŞKİN  
MELİH AKTAN

Division of Hematology, Istanbul Medical School, Istanbul, Turkey

ÖNER DOĞAN  
MEHMET AĞAN

*Division of Pathology, Istanbul Medical School, Istanbul, Turkey*

UĞUR ÖZBEK

*Institute for Experimental Medicine, University of Istanbul, Istanbul, Turkey*

KORAY DİNÇOL

*Institute of Oncology, University of Istanbul, Çapa, Istanbul, Turkey*

REFERENCES

1. Farcet JP, Gaulard P, Marolleau JP, Le Couedic JP, Henni T, Gourdin MF, Divine M, Haioun C, Zafrani S, Goossens M, Hercend T, Reyes F. Hepatosplenic T-cell

lymphoma: sinusal/sinusoidal localisation of malignant cells expressing the T-cell receptor  $\gamma\delta$ . *Blood* 1990;75:2213.

2. Cooke CB, Krenacs L, Stetler-Stevenson, Greiner TC, Raffeld M, Kingma DW, Abruzzo L, Frantz C, Kaviani M, Jaffe ES. Hepatosplenic T-cell lymphoma: a distinct clinicopathologic entity of cytotoxic  $\gamma\delta$  T-cell origin. *Blood* 1996;88:4265.
3. Dommann-Scherrer CC, Kurer SB, Zimmerman DR, Odermatt BF, Durs-Zimmermann MT, Briner J, Heitz PU. Occult hepatosplenic T-gamma delta lymphoma: value of genotypic analysis in the differential diagnosis. *Virchows Arch* 1995;426-629.
4. Salhany KE, Feldman M, Kahn MJ, Peritt D, Schretzenmair RD, Darren M, Wilson DM, Dipaola RS, Glick AD, Kant JA, Nowell PC, Kamoun M. Hepatosplenic  $\gamma\delta$  T-cell lymphoma: ultrastructural, immunophenotypic and functional evidence for cytotoxic T lymphocyte differentiation. *Hum Pathol* 1997;28:674.
5. Jansen J, Hermans J. Splenectomy in hairy cell leukemia: a retrospective multicenter analysis. *Cancer* 1981;47:2066.